Development and Scale-up of a Biocatalytic Process To Form a Chiral Sulfoxide
A Baeyer–Villiger monooxygenase enzyme has been used to manufacture a chiral sulfoxide drug intermediate on a kilogram scale.
Unit Operation: Process
Objective: Scale-Up
Company: AstraZeneca
Source: Org. Process Res. Dev., 2017, 21 (1), pp 107–113
Authors: Bradley Adams (AstraZeneca), Helen Benson (AstraZeneca), Julie Demeritt (AstraZeneca), William R. F. Goundry (AstraZeneca), Steven McKown (AstraZeneca), Keith Mulholland (AstraZeneca), Amy Robertson (AstraZeneca), Paul Siedlecki (AstraZeneca), Paula Tomlin (AstraZeneca), Kevin Vare (AstraZeneca)
Publish Date: 04-Jan-2017
Copyright © 2018 Scale-up Systems Ltd. | DynoChem Software and Development Services for the Pharma Industry | Privacy | Cookies | Contact